Neurocrine Biosciences (NBIX) Common Equity (2010 - 2026)
Neurocrine Biosciences (NBIX) posted quarterly Common Equity of $3.7 billion for Q2 2026, up 37.09% year-over-year from $2.7 billion in Q2 2025, and up 8.4% on a QoQ basis from $3.4 billion in Q1 2026.
Neurocrine Biosciences (NBIX) Common Equity (2010 - 2026) Analysis & Trends
Neurocrine Biosciences has reported Common Equity for 17 years, with the latest figure at $3.7 billion in Q2 2026.
- Common Equity for Q2 2026 came in at $3.7 billion, up 37.09% year-over-year; the trailing twelve-month figure through Jun 2026 was $3.7 billion (up 37.09% YoY), and the FY2025 annual result was $3.3 billion, up 25.62% from the prior year.
- Common Equity grew to $3.7 billion in Q2 2026, from $3.4 billion in the prior quarter.
- Over five years, Common Equity peaked at $3.7 billion in Q2 2026 and troughed at $1.4 billion in Q1 2022.
- A 5-year average of $2.4 billion and a median of $2.4 billion in 2024 frame the typical range for Common Equity.
- The widest annual swing landed in 2024, when Common Equity surged 41.65%; it then gained 6.27% in 2025.
- A 5-year view of Common Equity shows it stood at $1.7 billion in 2022, then jumped by 30.69% to $2.2 billion in 2023, then increased by 16.03% to $2.6 billion in 2024, then grew by 25.62% to $3.3 billion in 2025, then gained by 13.54% to $3.7 billion in 2026.
- Per Business Quant data, the three most recent Common Equity figures were $3.7 billion in Q2 2026, $3.4 billion in Q1 2026, and $3.3 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | 22.06 Bn |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn | 7.76 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 3.15 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 47.42 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn | 6.40 Bn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn | 14.26 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 3.69 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.59 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | 4.05 Bn |
| 10 | Alkermes | 8.12 Bn | 7.46 Bn | 397.90 Mn | 1.81 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.69 Bn |
| Mar 31, 2026 | 3.41 Bn |
| Dec 31, 2025 | 3.25 Bn |
| Sep 30, 2025 | 3.00 Bn |
| Jun 30, 2025 | 2.69 Bn |
| Mar 31, 2025 | 2.54 Bn |
| Dec 31, 2024 | 2.59 Bn |
| Sep 30, 2024 | 2.72 Bn |
| Jun 30, 2024 | 2.51 Bn |
| Mar 31, 2024 | 2.39 Bn |
| Dec 31, 2023 | 2.23 Bn |
| Sep 30, 2023 | 2.00 Bn |
| Jun 30, 2023 | 1.85 Bn |
| Mar 31, 2023 | 1.68 Bn |
| Dec 31, 2022 | 1.71 Bn |
| Sep 30, 2022 | 1.54 Bn |
| Jun 30, 2022 | 1.42 Bn |
| Mar 31, 2022 | 1.39 Bn |
| Dec 31, 2021 | 1.37 Bn |
| Sep 30, 2021 | 1.35 Bn |